EP2 receptor mediated cAMP release is augmented by PGF 2 alpha activation of the FP receptor via the calcium-calmodulin pathway

Citation for published version:
Abera, AB, Sales, KJ, Catalano, R, Katz, AA & Jabbour, HN 2010, 'EP2 receptor mediated cAMP release is augmented by PGF 2 alpha activation of the FP receptor via the calcium-calmodulin pathway', Cellular Signalling, vol. 22, no. 1, pp. 71-79. https://doi.org/10.1016/j.cellsig.2009.09.012

Digital Object Identifier (DOI):
10.1016/j.cellsig.2009.09.012

Link:
Link to publication record in Edinburgh Research Explorer

Document Version:
Publisher's PDF, also known as Version of record

Published In:
Cellular Signalling

Publisher Rights Statement:
Available under Open Access.

General rights
Copyright for the publications made accessible via the Edinburgh Research Explorer is retained by the author(s) and/or other copyright owners and it is a condition of accessing these publications that users recognise and abide by the legal requirements associated with these rights.

Take down policy
The University of Edinburgh has made every reasonable effort to ensure that Edinburgh Research Explorer content complies with UK legislation. If you believe that the public display of this file breaches copyright please contact openaccess@ed.ac.uk providing details, and we will remove access to the work immediately and investigate your claim.
EP2 receptor mediated cAMP release is augmented by PGF$_{2\alpha}$ activation of the FP receptor via the calcium-calmodulin pathway

A.B. Abera$^{a,b}$, K.J. Sales$^a$, R.D. Catalano$^a$, A.A. Katz$^b$, H.N. Jabbour$^{a,*}$

$^a$ MRC Human Reproductive Sciences Unit, The Queen’s Medical Research Institute, 47 Little France Crescent, Edinburgh EH16 4Jl, UK
$^b$ MRC/UCT Research Group for Receptor Biology, Institute of Infectious Disease and Molecular Medicine and Division of Medical Biochemistry, Faculty of Health Sciences, University of Cape Town, Cape Town, South Africa

A R T I C L E   I N F O

Article history:
Received 17 July 2009
Accepted 14 September 2009
Available online 25 September 2009

Keywords:
Prostaglandin
Adenylyl cyclase
CAMP
SAT1

A B S T R A C T

Prostaglandins exert their effects on target cells by coupling to specific G protein-coupled receptors (GPCRs) that are often co-expressed in the same cells and use alternate and in some cases opposing intracellular signaling pathways. This study investigated the cross-talk that influences intracellular signaling and gene expression profiling in response to co-activation of the EP2 and FP prostanoic receptors in Ishikawa cells stably expressing both receptors (FPEP2 cells). In this study we show that in FPEP2 cells, PGF alone does not alter adenosine 3’,5’-cyclic monophosphate (cAMP) production, but in combination with Butaprost enhances EP2 receptor mediated cAMP release compared to treatment with Butaprost alone. PGF-mediated potentiation of cAMP release was abolished by antagonism of the FP receptor, inhibition of phospholipase C (PLC) and inositol phosphate receptor (IP3R) whereas inhibition of protein kinase C (PKC) had no effect. Moreover, inhibition of calcium effectors using calmodulin antagonist (W7) or Ca2+/calmodulin-dependent kinase II (CaMK-II) inhibitor (KN-93) abolished PGF potentiation of Butaprost-mediated cAMP release. Using siRNA molecules targeted against the adenylyl cyclase 3 (AC3) isoform, we show that AC3 is responsible for the cross-talk between the FP and EP2 receptors. Using gene array studies we have identified a candidate gene, Spermidine/N1-acetyltransferase (SAT1), which is regulated by this cAMP mediated cross-talk. In conclusion, this study demonstrates that co-activation of the FP and EP2 receptors results in enhanced release of cAMP via FP receptor-Got$_{1},$Ca$^{2+}$-calmodulin pathway by activating calcium sensitive AC3 isoform.

© 2009 Elsevier Inc. All rights reserved.

1. Introduction

Prostaglandins exert paracrine and autocrine effects on target cells by coupling to specific G protein-coupled receptors (GPCRs) and activate intracellular signaling. PGE$_2$ and PGF$_{2\alpha}$ (PGF) are the most abundantly biosynthesized prostaglandins and are major metabolites of cyclooxygenase (COX) enzymes in the human endometrium [1,2]. Furthermore, COX enzyme expression, prostaglandins synthesis and their cognate receptors expression (mainly EP2 and FP) are dysregulated in endometrial adenocarcinoma [3–5].

EP2 and FP receptors are often co-expressed in the same cells and use different intracellular signaling pathways. EP2 receptors couple to G$_{14},$ resulting in increased formation of cAMP, while FP receptors couple to G$_{16},$ which in turn results in release of inositol-1,4,5-triphosphate (IP) and dicylgllycerol (DG) [6–8]. cAMP is generated in cells from adenosine triphosphate (ATP) by the enzymatic activity of the adenylyl cyclase (AC) family members. There are multiple AC isoforms (9 membrane-bound and 1 soluble) with different amino acid sequence, protein kinases (PKA, PKC, calcium and calcium-kinase) and phosphatases (calcineurin). Out of the ten AC isoforms three (AC1, AC3 and AC8) are calcium stimulated while AC5 and AC6 are normally inhibited by calcium in vivo [10,11]. The intracellular calcium pathway has been shown to play a significant part in AC$_{16}$-Go$_{16}$ cross-talk by regulating calcium sensitive AC isoforms [11–14]. For example, Ostrom et al. [13] showed a potentiation of $\beta$-adrenergic ($\beta$-AR) receptor induced cAMP production by activation of angiotensin II (ANG-II) receptor coupled to Go$_{16}$ protein through calcium/calmodulin pathway demonstrating cross-talk between ANG-II and $\beta$-AR receptors in cardiac fibroblasts.
GPCR cross-talk in the eicosanoid family has been shown in several studies. Walsh and Kinsella [15] showed a cross-talk between thromboxane A2 (TPx and TPγ) and EP1 receptors in HEK 293 cells that leads to desensitization and inhibition of signaling of the TP receptors in a PKC-dependent manner. The same group further indentified that the activation of the FP receptor by PGF can also mediate desensitization of the TPx and TPγ receptors via the PKC pathway [16]. In another study, Wilson et al. [17] showed that heterodimerization can occur between the human receptors for prostacyclin (IP) and TPα that leads to augmentation of TPα receptors-mediated accumulation of cAMP by IP receptors when they are co-expressed in a HEK 293 cell line.

Since EP2 and FP receptors are co-expressed in endometrial adenocarcinoma cells [7,18], this study investigated the cross-talk that may influence intracellular signaling and target gene activation in response to co-activation of EP2 and FP receptors.

2. Materials and methods

2.1. Reagents

All chemicals used were molecular biology grade and were obtained from Sigma (Dorset, UK or RSA) or IBI (Cambridge, UK). Cell culture media was purchased from Gibco (Gibco, Paisley, UK). Hygromycin (100 mg/ml stock) was purchased from Invitrogen (Invitrogen, Autogen Bioclear UK) while G418 (100 mg/ml stock in PBS), Indomethacin (3 mg/ml stock in ethanol), Butaprost (5 mM stock in ethanol), PGF (100 μM stock in ethanol) and 3-isobutyl-1-methyl xanthine (IBMX, 20 mM stock in 50% ethanol) were purchased from Sigma (Sigma chemical Co., Nottingham, UK). FP receptor antagonist (AL8810, 50 mM stock in ethanol), IP3R blocker (2-APB, 40 mM stock in DMSO), PLC inhibitor (U73122, 10 mM stock in DMSO), calmodulin (AL8810, 50 mM stock in ethanol), IP3R blocker (2-APB, 40 mM stock in DMSO), PLC inhibitor (U73122, 10 mM stock in DMSO), PKC inhibitor (Ro-31-822, 1 mM stock in DMSO) were all purchased from Calbiochem (Calbiochem, Nottingham, UK). Inhibitor of Gαo (YM254890, 1 mM stock in DMSO) was a kind gift from M. Taniguchi, (Astellas Pharmaceuticals Inc., Tokyo, Japan). The EP2 and FP receptor primary antibodies were purchased from Cayman Chemical Company (Axora, Nottingham, UK) and primary antibody for actin was purchased from Santa Cruz Biotechnology (Santa Cruz, Wiltshire, UK). Fluorescent secondary antibodies were purchased from Li-Cor Biosciences (Li-Cor Biosciences, Cambridge, UK). Stealth siRNA duplex oligoribonucleotides for AC1 and AC3 were purchased from Invitrogen (Invitrogen, Paisley, UK).

2.2. Cell culture

Ishikawa cells were maintained as described previously [18]. FPEP2 clones were maintained in G418 and hygromycin (200 μg/ml each) to select for the expression of EP and FP receptor, respectively.

2.3. EP2 receptor amplification and stable cell line transfection

To make stable cell lines expressing both EP2 and FP receptors, Ishikawa cells stably expressing the FP receptor (FPEP2 cell lines) were used as a parental cell line [7, 6]. cDNA from proliferative endometrium was synthesised as previously described [6] and EP2 receptor was amplified using forward 5′-TCTCTTTTCCAGGCACCAC-3′ and reverse 5′-TTTTAAGTACTGACCTAAGGTC-3′ primers. EP2 receptor cDNA was ligated into the pcDNA3.1 (Invitrogen) expression vector in both sense and antisense directions and was transfected to the FPEP2 cells using SuperFect® transfection reagent (Qiagen, UK) according to manufacturer’s recommendations. Transfected cells were selected in a medium containing 800 μg/ml of hygromycin in parallel with untransfected cells. Once untransfected cells had died, hygromycin-resistant clones were picked and expanded under the selective medium. Clones were then screened for the expression of the EP2 receptor by quantitative real-time RT-PCR and for their ability to produce intracellular cAMP in response to Butaprost treatment. Three FPEP2 clones (clones 4, 8 and 10) with similar expression levels and biochemical characteristics were selected for further investigation. Data on FPEP2 clone 8 is presented here, with similar data obtained using the other two clones.

2.4. cDNA synthesis and real-time RT-PCR

Total RNA was extracted from Ishikawa cells using Tri-Reagent (Sigma-Aldrich Corp., Poole, UK) as manufacturer’s recommendations and cDNA was synthesised from total mRNA as described previously [18]. Thereafter, quantitative real-time RT-PCR was performed with specific E and F prostanoid (EP1, EP2, EP3, EP4 and FP receptors), AC1, AC3 and SAT1 primers and probes (Table 1) as described previously [18]. Expression of analyzed genes was normalized to RNA loading for each sample using the 18S ribosomal RNA as an internal standard. Results are expressed as fold increase above vehicle treated cells. Data are presented as mean ± SEM from at least 3 independent experiments.

2.5. Protein extraction from cells, SDS-PAGE and western blotting

Ishikawa cells were seeded at a density of 5 × 10⁵ cells in 6 cm dishes overnight. The following day protein was extracted from the cells as described previously [18]. Total protein was quantified using standard BIO-RAD DC assay (Bio-Rad, Hemel Hempstead, UK) as directed by the manufacturer’s instruction. A total of 40 μg of protein was resuspended in 1× Laemmli buffer (125 mM Tris–HCL pH 6.8, 4% SDS, 20% glycerol, 0.05% bromophenol blue) and boiled for 5 min at 95 °C. Samples were resolved and immunoblotted as described previously [18] prior to incubating with the rabbit anti-EP2 or FP receptor in combination with goat anti-actin primary antibody (all in 1:1000) at 4 °C overnight. The membrane was then washed with PBS-Tween and incubated with the secondary fluorescence donkey anti-rabbit IgG conjugated to Alexa Fluor 680.
(Invitrogen) and donkey anti-goat IgG conjugated to IRDYE 800 (Tebu-bio, Peterborough, UK) for 1h in the dark at 25 °C. After washing the membrane proteins were then viewed using Odyssey Infrared imaging system (Li-Cor Bioscience, Cambridge, UK).

2.6. Immunofluorescence microscopy of cells

The site of EP2 and FP receptor expression in FPS32 and FPEP2 cells were localised using immunofluorescence microscopy as described previously [19]. Briefly, 100,000 cells/well were plated out in 2-well cell chamber slides and left to adhere overnight. The next day cells were fixed with ice-cold 4% paraformaldehyde (PFA) for 20 min and washed with PBS, before being blocked by 5% BSA diluted in normal goat serum for 2 h. Thereafter, the cells were incubated with polyclonal rabbit anti-EP2 and FP receptor antibody diluted in normal goat serum (1:100) overnight at 4 °C. The next day, cells were washed three times in PBS for 10 min and incubated with Alexa Flour 488 goat anti-rabbit IgG (1:200 in PBS; Molecular Probes) for 2 h. Slides were counterstained with DAPI (1:1000 in PBS; Sigma) for 10 min for nuclear visualisation, washed and mounted in Permaflour (Immunotech-Coulter, Buckinghamshire, United Kingdom) and coverslipped for microscopic analysis. Control cells were incubated with preadsorbed primary antibodies with a specific immunogen blocking peptide.

2.7. Ligand stimulation and cAMP assay

Butaprost and/or PGF-induced cAMP accumulation was determined by seeding 2 × 10^5 Ishikawa cells/well in 6-well plates. The cells were serum-starved in the presence of 3 µg/ml of indomethacin (a dual Cox enzyme inhibitor used to inhibit production of endogenous prostaglandins). Thereafter, the cells were pre-treated with the phosphodiesterase inhibitor IBMX (Sigma) to a final concentration of 0.2 mM in serum-free medium for 30 min. Cells were treated for 5 min with vehicle, Butaprost (5 µM) and/or PGF (100 nM) in the presence/absence of different chemical inhibitors as described in the figure legends. After incubation the cells were lysed in R&D Cell Lysis Buffer™ (R&D Systems, Oxford UK) and cAMP release was determined by ELISA using cAMP Kit (R&D Systems) according to manufacturer's protocol. The concentration of cAMP was calculated using a standard curve by Assay Zap (Biosoft, Cambridge, UK) and was normalized.

Fig. 1. EP2 and FP receptor analysis in FPS32 and FPEP2 cells. Relative mRNA expression of (A) EP2 receptor (B) EP1, EP3, EP4 and FP receptors as determined by quantitative real-time RT-PCR analysis in FPS32 and FPEP2 cells. Expression levels in FPEP2 clones are expressed as fold increase above FPS32 cells (n = 4; **P < 0.0001). (C) Protein expression of FP and EP2 receptors normalized for loading against β-actin and expressed as fold increase above FPS32 cells as determined by Western blot analysis. (D) Localization of the FP (FPR) and EP2 (EP2R) receptor in FPS32 and FPEP2 cells as determined by immunofluorescence microscopy. Control cells (C) were incubated with preadsorbed primary antibody using specific blocking peptides. (E) The effect of 5 and 10 min treatments with vehicle or Butaprost on cAMP release in FPS32 and FPEP2 cells as determined by cAMP ELISA analysis (n = 4; **P < 0.001; ***P < 0.0001). (F) The effect of 60 min PGF stimulation on IP response in FPS32 and FPEP2 cell lines. Data are expressed as fold increase above non-stimulated samples (n = 5).
according to the respective protein concentration of each sample. Data are represented as mean ± SEM.

2.8. Total inositol phosphate (IP) assay

PGF and/or Butaprost-induced accumulation of IP was determined as previously described [20]. Briefly, Ishikawa cells (50,000 cells/well) were seeded in 24-well plates and allowed to adhere overnight. The following day, cells were labeled with 0.5 µCi/well myo-[3H]-inositol (Amersham Biosciences, RSA) in an inositol-free DMEM 199 media supplemented with 2% dialyzed fetal calf serum overnight. The next day, cells were stimulated with PGF and/or Butaprost with the required concentration for an hour at 37 °C while non-stimulated samples were taken as control for each experiment. After aspirating the buffer, cells were lysed by the addition of 1 ml ice-cold 10 mM formic acid and the plates were placed on ice for 30 min. Total [3H]-inositol phosphates were separated from cell extracts on AG 1-X8 resin by anion exchange chromatography and counted by scintillation counting in Liquid Scintillation Analyzer (Packard GmbH, Frankfurt, Germany). Data are represented as mean ± SEM and expressed as fold increase above non-stimulated samples.

2.9. Knockdown of AC1 and AC3 with siRNA transfection

Three different Stealth siRNA duplex oligoribonucleotides (Invitrogen, Paisley, UK) were used to abrogate the expression and function of AC1 and AC3. FPEP2 Ishikawa cells were seeded (7.5×10⁴ cells/well) in complete media into 12-well plates. On the day of the transfection, the cells were exposed to 60 nM (20 nM from each Stealth siRNA) AC isoform-specific or scrambled sequence siRNA in the presence of SuperFect® (QIAGEN, Crawley, UK) for 6 h. After 48 h of transfection, the cells were subjected to RNA extraction for AC1 and AC3 mRNA expression analysis or serum-starved overnight in medium containing indomethacin (3 µg/ml) for cAMP assay. For cAMP assay, cells were then exposed to either Butaprost (5 µM) and/or PGF (100 nM) for 5 min, lysed and subjected to cAMP analysis as described earlier.

2.10. Gene array and data analysis

Ishikawa FPEP2 cells were seeded at a density of 5×10⁵ cells, serum-starved for 18 h in the presence of 3 µg/ml of indomethacin. Cells were then treated in serum-free media for 8 h with vehicle, Butaprost (5 µM) and/or PGF (100 nM). Treatments were performed in triplicate and repeated four times, (total of n = 12 for each treatment). After treatment, the cells were washed with ice-cold PBS, total RNA was extracted from each sample, RNA was analyzed and triplicates pooled to produce four samples of each treatment for array analysis. RT-IVT was then carried out in accordance to the Applied Biosystems Chemiluminescent RT-IVT nanoamp (one-cycle) labelling protocol. Samples were fragmented and hybridized to ABI700 version 2 Applied Biosystems Human Genome Survey microarrays. After hybridization the GeneChip arrays were stained and washed on the fluidics station and scanned. Data acquired using ABI technology was pre-processed according to the manufacturers’ recommendations. The data was normalized using variance stabilized normalization [21]. Normalized data were analyzed for differential expression with the LIMMA package as described in the LIMMA user guide [22]. The P values were adjusted for multiple testing with Benjamini and Hochberg method [23]. The resulting gene list included only the genes that had a fold change value of 2.0 or higher and a P of <0.05. Bioinformatics was performed using the gene set

Fig. 2. PGF enhances Butaprost-stimulated cAMP production via FP receptor-Gqα coupling and PLC activation. (A) IP release in FPEP2 cells after treatment with PGF (10⁻¹⁰ to 10⁻⁶ M) or (5 µM) Butaprost alone or PGF (10⁻¹⁰ to 10⁻⁶ M) and Butaprost (5 µM) together for 60 min as determined by an IP assay. Data are expressed as fold increase above non-stimulated sample (n = 4). (B) cAMP accumulation in FPEP2 cells after 5 min treatment with vehicle, Butaprost and/or PGF (n = 4). (C) cAMP accumulation in FPEP2 cells treated with vehicle, Butaprost and/or PGF in the presence/absence of the EP2 receptor antagonist (AH6809), FP receptor antagonist (AL-8810) or Goq inhibitor (YM-254890) for 5 min (n = 4). (D) cAMP in cells treated with vehicle Butaprost and/or PGF or Butaprost and/or PGF together with the PLC inhibitor (10 µM U73122), IP3-R blocker (40 µm 2-APB) or PKC inhibitor (1 µm Ro-31-822) for 5 min (n = 4; **,** P<0.001).
analysis tool kit [24]. A hypergeometric test was used to calculate significantly overrepresented ontologies from the gene list. Array hybridization and data analysis was performed by GeneService Ltd (Cambridge, UK). Gene Ontology annotations were assigned to classify Butaprost and/or PGF regulated genes for biological processes and molecular functions using a web tool provided by the gene ontology database (www.geneontology.org).

2.11. Statistical analysis

All data are presented as mean± S.E.M. Statistical significant differences were determined by one-way analysis of variance using Prism 5.0 software (GraphPad Software Inc., San Diego, CA) (*, P<0.05; **, P<0.001; ***, P<0.0001).

3. Results

3.1. EP2 and FP receptor expression in stably transfected Ishikawa cells

In order to investigate the cross-talk between the EP2 and FP receptors, we created a stable cell line expressing the EP2 and FP receptor in Ishikawa cells (FPEP2 cells). We initially assayed the expression of the E prostanoid receptors (EP1, EP2, EP3 and EP4) and FP receptor in FPEP2 cells in comparison with the parental FPS32 cells. As shown in Fig. 1A, quantitative real-time RT-PCR revealed a significant increase of EP2 receptor expression above the parental FPS32 cells (P<0.0001). There was no significant difference in expression of EP1, EP3, EP4 and the FP receptor between the FPEP2 cell line and the parental FPS32 cell line (Fig. 1B). Western blot analysis (Fig. 1C) and immunofluorescence microscopy (Fig. 1D) confirmed elevated expression of EP2 receptor protein in the FPEP2 cells compared to the FPS32 cells while the FP receptor expression was not altered between the two cell lines.

Activation of the EP2 receptor by Butaprost leads to intracellular accumulation of cAMP [25]. In order to assess the functionality of the EP2 receptor in FPEP2 cells, the ability to generate cAMP was determined by treating the cells with vehicle or Butaprost (5 μM) for 5 and 10 min. As shown in Fig. 1E, treatment of FPEP2 cells with Butaprost for 5 or 10 min increased intracellular cAMP accumulation significantly (P<0.001 and P<0.0001, respectively) in a time-dependent manner compared to vehicle treatment. Butaprost treatment of the FPS32 cell line had no effect on intracellular cAMP accumulation compared to vehicle treatment (Fig. 1E).

The FP receptor is a Goq-coupled receptor, which upon PGF activation leads to an accumulation of intracellular IP [25]. In order to compare the functionality of the FP receptors in the parental FPS32 and FPEP2 cell lines, the cells were subjected to increasing doses of PGF administration (10^{-10} to 10^{-6} M) while control samples were left untreated for an hour. As shown in Fig. 1F, PGF treatment of both the parental FPS32 and FPEP2 cells lines gave a dose-dependent increase in IP release with an E_{max} value of 15.7±6.6 and 16.6±2.1 and an E_{50} value of 2.3 nM±0.3 and 1.95 nM±0.8 for the FPS32 and FPEP2 cell lines respectively, confirming our observations in Fig. 1B and C, that the levels of FP receptor were similar between the FPS32 and FPEP2 cells.

3.2. PGF potentiates Butaprost-stimulated cAMP production via FP receptor-Goq coupling and PLC activation in FPEP2 Ishikawa cells

We next determined the integrated effect of Butaprost and PGF co-administration on IP and cAMP release. FPEP2 cells were treated with an increasing dose of PGF (10^{-10} to 10^{-6} M) or 5 μM Butaprost alone or with PGF (10^{-10} to 10^{-6} M) and 5 μM of Butaprost together. As shown in Fig. 2A, Butaprost treatment of the FPEP2 cells had no effect on IP release, since treatment of PGF alone or in combination with Butaprost gave a similar IP response (E_{max} 15.5±6.6 and E_{max} of 16.6±2.2 and E_{50} 0.7 nM±0.5 and 1.95±1.04, respectively). These data demonstrate that PGF-mediated IP release is not affected by Butaprost treatment. To assess the effect of FP receptor induction by PGF on Butaprost-stimulated cAMP accumulation, FPEP2 cells were treated with vehicle, Butaprost (5 μM) and/or PGF (100 nM) for 5 min. As shown in Fig. 2B, treatment of cells with Butaprost alone gave a robust increase in intracellular cAMP accumulation compared with vehicle treatment (P<0.001), while treatment with PGF alone had minimal effect. However, co-treatment of the cells with Butaprost and PGF together significantly increased the cAMP response compared to treatment with Butaprost alone (Fig. 2B; P<0.001).

To investigate whether the augmentation of cAMP release by PGF is mediated by either the EP2 or FP receptor, FPEP2 cells were treated with Butaprost and/or PGF in the presence/absence of specific antagonist for the EP2 receptor (AH6809; 10 μM) or FP receptor (AL-8810; 50 μM). As shown in Fig. 2C, antagonism of the EP2 receptor significantly decreased (P<0.001) Butaprost-induced cAMP release in

![Fig. 3. PGF potentiates Butaprost-stimulated cAMP through calmodulin-CaMK-II pathway by activating AC3 isoform in FPEP2 cells.](image-url)
both groups (Butaprost only and Butaprost and PGF). In contrast, the FP receptor antagonist only abolished the potentiation of cAMP by PGF without altering basal and Butaprost-stimulated cAMP (P < 0.001).

To assess if the PGF potentiation of Butaprost-stimulated cAMP is mediated by FP receptor-Gαq coupling, FPEP2 cells were treated with Gαq inhibitor (YM-254890; 1 μM) in the presence/absence of Butaprost and/or PGF. As shown in Fig. 2C, the use of Gαq inhibitor significantly reduced the level of PGF and Butaprost-stimulated cAMP to the level observed in the Butaprost-treated cells (P < 0.001). These data indicate that, PGF potentiation of Butaprost-stimulated cAMP is mediated via the FP receptor activation of Gαq.

PGF activated FP receptor-Gαq coupling leads to activation of PLC that results in both IP release, to increase intracellular calcium and DAG release that activates PKC [7,26]. We assessed whether the PKC-mediated enhancement of Butaprost-stimulated cAMP was via the PLC-IP or PLC-PKC pathway. As shown in Fig. 2D, inhibition of PLC using the PLC inhibition U73122 (10 μM) abolished the augmentation shown by PGF demonstrating this Gαq–Gαq cross-talk is mediated by PLC activation. In order to determine whether intracellular calcium or PKC activation mediate the observed cross-talk, the cells were incubated with specific IP3R blocker (2-APB; 40 μM) or PKC inhibitor (Ro-31–822; 1 μm) in the presence of Butaprost and/or PGF. Co-treatment of the cells with 2-APB significantly inhibited (P < 0.001) the PGF-mediated increase in Butaprost-induced cAMP release but had no effect on Butaprost treatment alone. Whereas inhibition of PKC had minimal effect on reducing the PGF-mediated augmentation of cAMP demonstrating that PGF-mediated increase in cAMP is via the accumulation of intracellular calcium (Fig. 2D).

3.3. PGF-induced cAMP potentiation is mediated by intracellular Ca2+ transients and activation of the AC3 isoform in FPEP2 Ishikawa cells

Intracellular calcium is known to modulate calcium sensitive isoforms of AC to enhance cAMP production via activation of calmodulin-CaMK-II pathway [27]. To determine whether the PGF-mediated enhancement of cAMP is regulated by the calcium-calmodulin pathway, chemical inhibitors against two calcium effectors were used. Inhibition of calcium pathway, using calmodulin antagonist (W7; 25 μM) or CaMK-II inhibitor (KN-93; 50 μm) significantly reduced (P < 0.001) the level of cAMP release seen in FPEP2 cells treated with the combination of Butaprost and PGF to Butaprost-stimulated level (Fig. 3A). These results indicate that PGF potentiation of Butaprost-stimulated cAMP is by the release of Ca2+ from intracellular stores leading to activation of calmodulin-CaMK-II pathway.

To investigate which AC isoforms are present in FPEP2 cells, RT-PCR was performed using AC isoform-specific primers. We found that Ishikawa cells express mRNA for AC1, AC3, AC4, AC5, AC6, AC7, AC9 and the soluble AC (SAC), but not AC2 or AC8 isoforms (data not shown). Out of the eight isoforms expressed in Ishikawa cells two of them are known to be calcium stimulated (AC1 and AC3) [11]. Calcium-regulated AC isoforms have been suggested to be involved in Gαq–Gαq cross-talk [12–14,28]. To identify which AC isoform is involved in the EP2-FP receptor cross-talk, siRNA designed to AC1 and AC3 were used to knockdown endogenous mRNA expression of the specific isoforms. After specific siRNA transfection into FPEP2 cells, quantitative real-time RT-PCR showed that AC1 and AC3 mRNA expressions were reduced by 76% and 70% respectively compared with scrambled sequence siRNA

Table 2

| Gene | Description | Mean fold change | Butaprost | PGF and Butaprost |
|------|-------------|-----------------|-----------|-------------------|
| SAT1 | Spermadine/spermine N1-acetyltransferase | Enzyme in the pathway of polyamine metabolism | 5.94 | 7.47 |
| RAPGEF5 | Rap guanine nucleotide exchange factor (GEF) 5 | GTPase function in signal transduction | 3.48 | 4.05 |
| FRAS1 | Frasier syndrome 1 | Extracellular matrix protein, adhesion | 3.46 | 6.41 |
| KCN5 | Potassium channel, subfamily K, member 5 | Potassium channel | 3.20 | 3.71 |
| ATP1B3 | ATPase, Na+/K+ + transporting, beta 3 polypeptide | Establishing and maintaining gradients of Na and K ions | 3.19 | 4.28 |
| AQPD | Aquaporin 3 | Water channel protein | 3.03 | 3.57 |
| CDC42EP2 | CDC42 effector protein 2 | Actin filament assembly and cell shape control | 3.02 | 4.16 |
| LIM3 | LIM and senescent cell antigen-like domains 3 | Unknown | 2.98 | 3.81 |
| FAM100A | Family with sequence similarity 100, member A | Unknown | 2.87 | 3.55 |
| ZNF532 | Zinc finger protein 323 | Embryonic development | 0.16 | 0.12 |
| NR3C2 | Nuclear receptor subfamily 3, group C, member 2 | Mineralocorticoid receptor | 0.18 | 0.14 |
| SPAG8 | Sperm associated antigen 8 | Tumor progression | 0.24 | 0.15 |
| C10orf91 | Chromosome 10 open reading frame 91 | Unknown | 0.27 | 0.14 |
| DEFB1 | Defensin, beta 1 | Antimicrobial peptide | 0.32 | 0.29 |
| KIAA1305 | KIAA1305 | Unknown | 0.32 | 0.23 |
| ALDH3B2 | Aldehyde dehydrogenase 3 family, member B2 | Detoxification of aldehydes | 0.33 | 0.29 |
| RNFI44B | Ring finger protein 144B | Regulate the stability of p21 | 0.33 | 0.27 |
| SYNUX | Synam | Intermediate filament protein | 0.34 | 0.26 |
| MSA2 | Membrane-spanning 4-domains, subfamily A, mem 2 | Subunit of the high affinity Ig receptor | 0.34 | 0.29 |
| RELA | Relatin 1 | Endocrine and autocrine/paracrine hormone | 0.35 | 0.32 |
| OR6W1P | Olfactory receptor, family 6, subfamily W, member 1 pseudogene | Pseudogene | 0.35 | 0.29 |
| TRIM6 | Tripartite motif-containing 6 | Antitoxin | 0.35 | 0.30 |
| SAMD13 | Sterile alpha motif domain containing 13 | Unknown | 0.35 | 0.31 |
| CYP26A1 | Cytochrome P450, family 26, subfamily A, polypeptide 1 | Regulates the cellular level of retinoic acid | 18.03 | 12.28 |
| PRTR | Reprimo, TP53 dependent G2 arrest mediator | Potential tumor suppressor | 11.90 | 7.76 |
| IL1R2 | Interleukin receptor, type II | Receptor that inhibits the activity of its ligands | 3.98 | 3.62 |
| BTB2 | BTB (POZ) domain containing 3 | Proliferation and anti-apoptosis | 3.30 | 3.02 |
| ZNF703 | Zinc finger protein 703 | Repressor of transcription | 3.28 | 3.04 |
| ADA | Adenosine deaminase | Catalyzes the hydrolysis of adenosine to inosine | 3.15 | 2.87 |
| C1orf168 | Chromosome 1 open reading frame 168 | Unknown | 0.23 | 0.31 |
| DDIT4 | DNA-damage-inducible transcript 4 | Mediator in RAS-mediated transformation | 0.22 | 0.26 |
| LIPC | Lipase, hepatic | Triglyceride hydrolase and factor for lipoprotein uptake | 0.19 | 0.22 |
| VWA5A | Von Willebrand factor A domain containing 5A | Potential tumor suppressor | 0.17 | 0.23 |
| KCNJ5 | Potassium channel, subfamily J, member 5 | Potassium channel | 0.16 | 0.22 |
transfection (Fig. 3B). The specificity of the siRNA was also proven as both AC1 and AC3 siRNA inhibited the expression of their cognate targets without altering the other (Fig. 3B). After 48 h of siRNA transfection, cells were exposed to either Butaprost and/or PGF for 5 min. Thereafter, cells were lysed and subjected to cAMP analysis as described earlier to assess the functional effect of the knockdown. As shown in Fig. 3C, transfection with AC3 siRNA completely abolished the potentiation of Butaprost-stimulated cAMP by PGF significantly (P < 0.001) while AC1 siRNA transfection had no effect on cAMP accumulation. This result demonstrates that PGF can enhance Butaprost-stimulated cAMP via the FP receptor-Gαq-Ca2+-calmodulin pathway by activating the calcium sensitive AC3 isoform.

3.4. Gene array analysis

Gene array analysis was used to identify downstream gene transcriptional changes influenced by PGF-enhanced Butaprost-stimulated CAMP signaling. Ishikawa FPEP2 cells were treated with vehicle, Butaprost and/or PGF for 8 h. RNA was extracted, hybridized to AB1700 gene chips, and subjected to gene array analysis. The analysis identified 34 genes whose expression was not regulated by PGF alone, but altered in response to Butaprost and PGF co-treatment compared to treatment with Butaprost alone (Table 2). For example SAT1 gene expression was enhanced from a 5.9 fold increase to a 7.5 fold increase, whereas cytochrome P450, family 26, subfamily A, polypeptide 1 (CYP26A1) gene expression was repressed from an 18.0 fold increase to a 12.3 fold increase. To determine whether the list contained genes with common functions the Gene Ontology database was used to group the genes into functional ontologies. Three functional groups were identified which were represented by 5 or more genes, those for cellular metabolism, immune response and excretion.

3.5. Butaprost-mediated SAT1 gene expression is potentiated by Gαq–Gαs cross-talk

Since our array analysis has demonstrated a unique subset of genes, whose expression induced by Butaprost was modulated by PGF, we next investigated the integrated Gαq–Gαs cross-talk regulating downstream transcriptional activation by analyzing a candidate gene SAT1, selected from the gene list (Table 2). We focused on the regulation of this gene since it is known to be regulated by cAMP via the CAMP response element binding protein (CREB) that is located on its promoter region [34]. To study the temporal expression of this gene, FPEP2 Ishikawa cells were treated with vehicle, Butaprost and/or PGF for 4, 6 and 8 h. As shown in Fig. 4A, Butaprost treatment alone significantly increased expression of SAT1 at all time points compared to vehicle treatment (P < 0.001). No significant elevation of SAT1 gene expression was observed following PGF treatment alone. However, co-stimulation of FPEP2 cells with Butaprost and PGF enhanced the Butaprost-stimulated expression of SAT1 significantly at all time points (P < 0.001). To determine whether the PGF-mediated potentiation of SAT1 expression is mediated by the FP receptor, the cells were treated with the FP receptor antagonist (AL8810) in the presence/absence of Butaprost and/or PGF for 6 h. As shown in Fig. 4B, antagonism of the FP receptor completely abolished the potentiation of SAT1 expression by PGF without altering Butaprost-stimulated expression of SAT1. These data demonstrate that Butaprost-regulated expression of SAT1 is augmented by PGF-FP receptor coupling.

Since we have shown that AC3 is involved in the Gαq–Gαs cross-talk in FPEP2 cells, we assessed if the same isoform is involved in PGF-mediated potentiation of SAT1 expression. As shown in Fig. 4C, ablation of AC3 expression reduced SAT1 mRNA expression in FPEP2 cells treated with the combination of Butaprost and PGF to the level observed following stimulation with Butaprost alone (P < 0.001). These data demonstrate that PGF-mediated potentiation of SAT1 mRNA expression is mediated by the EP2-FP receptor cross-talk via the FP receptor activation of the calcium sensitive AC3 isoform.

4. Discussion

There is mounting evidence to support a role for prostaglandins and their respective receptors in endometrial pathologies such as dysmenorrhoea, endometriosis, menstruation and endometrial adenocarcinoma [3,5,29,30]. Studies in our laboratory and others have used a reductionist approach to dissecting the signaling pathways following the activation of individual EP2 or FP receptors in numerous cell types. We have shown activation of the EP2 and FP receptors can lead to phosphorylation of ERK1/2 via the activation of c-Src and transphosphorylation of the epidermal growth factor receptor (EGFR) in Ishikawa cells and endometrial adenocarcinoma explants ex vivo [7,18]. In addition others have shown activation of the EP2 receptors can trigger the Wnt signaling pathway that involves phosphorylation of glycogen synthase kinase-3 (GSK-3) by Akt to activate β-catenin mediated transcriptional activation in HEK 293 cells [31].
Prostanoid receptors are co-expressed in many cell types [32]. This suggests that co-activation of prostanoid receptors in the same cell could alter the physiological/pathophysiological gene expression profile and outcome. However, to our knowledge there have been no studies addressing the integrative signaling effects of the EP2 and FP receptors on signal transduction and gene expression. Here we show for the first time that co-activation of prostanoid receptors can alter the gene expression profile in endometrial adenocarcinoma cells stably expressing the EP2 and FP receptors. In addition to our knowledge this is the first study to investigate the cross-talk between the EP2 and FP receptors and the molecular mechanism underlying the intracellular signaling pathway in response to co-activation of both receptors.

In order to investigate prostanoid integrative signaling, we stably transfected the EP2 receptor into Ishikawa cells stably expressing the FP receptor. Expression level of the EP2 receptor in FPEP2 cells was compared to the parental FPS32 cells using quantitative real-time RT-PCR. Western blot analysis and immunofluorescence microscopy confirming stable expression of EP2 receptor in FPEP2 cells localised to the perinuclear and plasma membrane. Introduction of the EP2 receptor had no effect on the expression profile of the other E-series receptors and of FP receptor which could be activated by prostanoid ligands in our study. Furthermore, the functionality of EP2 and FP receptors was also confirmed by the release of their respective secondary messengers, cAMP and IP in the presence of their respective ligands.

Using the FPEP2 cells as a model system, we showed that Butaprost stimulation of FPEP2 cells gave a robust intracellular accumulation of cAMP while PGF-mediated FP receptor activation by its own had no effect on cAMP production. Interestingly we found that PGF could significantly enhance the cAMP accumulation in combination with Butaprost. Using specific receptor antagonists and small molecule chemical inhibitors of cell signaling we dissected the signaling pathways mediating the PGF-induced augmentation of cAMP in cells treated with the combination of ligands and have shown that the PGF-enhancement of cAMP observed in FPEP2 cells treated with Butaprost and PGF was induced via the FP receptor-Gαs-mediated activation of IP via PLC. Following its release IP could activate its receptors (IPR) present on the endoplasmic reticulum (ER) membrane to promote intracellular calcium release and activation of calmodulin and CaMK-II as depicted schematically in Fig. 5. Numerous studies have shown that the CaMK-II pathway can activate calcium sensitive AC isoforms to regulate intracellular cAMP accumulation [12–14,27,28]. We identified AC1 and AC3 as calcium-regulated targets in our FPEP2 cells by RT-PCR analysis. Transfection studies using siRNA to abolish expression of AC1 or AC3 in FPEP2 cells revealed that the calcium sensitive AC3 (but not AC1) isoform is responsible for PGF-mediated potentiation of Butaprost-stimulated cAMP. These data suggest that the cAMP mediated Gαs–Gαq cross-talk reported here is via the activation of the calcium sensitive isoform AC3.

There has been other cAMP mediated Gαs–Gαq cross-talk reported but only one with physiological relevance [12–14]. The Gαs–Gαq cross-talk reported by Ostram et al. [13] had an important physiological consequence on regulation of the extracellular matrix in myocardium. The authors showed β-adrenergic receptor mediated inhibition of collagen synthesis was further decreased by co-activation of angiotensin II receptor suggesting the cross-talk might play a role in inhibition of fibrosis in heart. In order to determine the integrative effects of receptor co-activation on gene expression, we performed whole genome array profiling in FPEP2 cells in response to Butaprost, PGF or the combination of Butaprost and PGF. Co-activation of FPEP2 cells with Butaprost and PGF enhanced or repressed a set of Butaprost (EP2 receptor) regulated genes. Analysis of the gene list for Gene Ontology annotations indicated functions in cellular metabolism, immune response and excretion. One of the genes identified, SAT1 is an important enzyme in polyamine metabolism, adding an acetyl group to aminopropyl ends of spermidine and spermine [33]. The promoter region of SAT1 lacks TATA box but has multiple binding sites for transcriptional factors including CREB, suggesting it is cAMP regulated [34]. We investigated the integrative signaling mediating the role of prostanoids on SAT1 expression in FPEP2

![Fig. 5. Gαq-mediated potentiation of Butaprost-induced cAMP release. Butaprost activates Gαq-coupled EP2 receptors resulting in a rapid increase in intracellular cAMP accumulation while PGF by itself does not alter cAMP production. However, co-treatment of the cells with both ligands leads to the Gαq-mediated activation of PLC and release of IP3 from the plasma membrane. Subsequently, IP3 via the IP3 receptor (IP3R) mediates the release of Ca2+ from intracellular stores leading to calmodulin-CaMK-II dependent potentiation of cAMP release via the calcium sensitive AC3 isoform and modulation of gene transcription such as SAT1.](image)
cells. We found that SAT1 is regulated by the cAMP mediated Gαq–Gqα cross-talk via AC3, such that siRNA knockdown of the AC3 isoform completely inhibited the potentiation of Butaprost-stimulated SAT1 expression by PGF. SAT1 is a highly regulated enzyme and it is inducible by polyamines and has been shown to be involved in carcinogenesis [35]. A transgenic increase of SAT1 expression in mice showed a variety of defects such as hair loss, female infertility, impaired lipid metabolism and predisposition to develop pancreatitis [36]. Tucker et al. [37] showed SAT1-over producing transgenic mice bred with Apoc3−/− mice (mice predisposed to intestinal tumor formation) had an increase in incidence of intestinal tumors while crosses with SAT1 knockout mice led to 75% reduction in tumor load.

Although the role of SAT1 in endometrial pathologies with dysregulated prostanooids is unclear, SAT1 has been shown to have a direct effect on cell migration by binding with α9β1-integrin [38]. Moreover, in a recent study, Vlahakis et al. [39] have demonstrated that α9β1-integrin can bind to the vascular endothelial growth factor (VEGF) to promote angiogenesis. In light of these studies, SAT1 might play a role in pathologies of endometrium by directly promoting cell migration and an indirect enhancement of angiogenesis via α9β1-integrin.

5. Conclusions

This study demonstrates that co-activation of the EP2 and FP receptors results in enhanced release of cAMP, in a Gαq-calcium-dependent manner via the calcium sensitive AC3 isoform. Activation of this pathway modulates expression of genes involved in metabolism, immune response and excretion. Taken together our data suggest that when both EP2 and FP receptors are co-activated this leads to a unique integrative signaling pathway that modulates downstream gene expression of a subset of EP2 receptor induced genes.

Acknowledgements

This study was supported by MRC core funding to HNJ (U.1276.00.004.00002.01) and by the South African MRC to AK.

References

[1] S. Narumiya, Y. Sugimoto, F. Ushikubi, Physiol. Rev. 79 (4) (1999) 1193.
[2] K.J. Sales, H.N. Jabbour, Prostaglandins Other Lipid Mediat. 71 (3–4) (2003) 97.
[3] K.J. Sales, H.N. Jabbour, Reproduction 126 (5) (2003) 559.
[4] M.C. Rees, A.B. Anderson, L.M. Demers, A.C. Turnbull, Br. J. Obstet. Gynaecol. 91 (7) (1984) 673.
[5] S.K. Smith, M.H. Abel, R.W. Kelly, B.T. Baird, Br. J. Obstet. Gynaecol. 88 (4) (1981) 434.
[6] H.N. Jabbour, S.A. Milne, A.R. Williams, R.A. Anderson, S.C. Boddy, Br. J. Cancer 85 (7) (2001) 1023.
[7] K.J. Sales, T. List, S.C. Boddy, A.R. Williams, R.A. Anderson, Z. Naor, H.N. Jabbour, Cancer Res. 65 (17) (2005) 7707.
[8] S.A. Milne, H.N. Jabbour, J. Clin. Endocrinol. Metab. 88 (4) (2003) 1825.
[9] J. Krupinski, F. Cousens, H.A. Bakalyar, W.J. Tang, P.G. Feinstein, K. Orth, C. Slaughter, R.R. Reed, A.G. Gilman, Science 244 (4912) (1989) 1558.
[10] J. Hanoune, Y. Pouille, E. Tazava, T. Shen, L. Lipkays, N. Miyamoto, Y. Suzuki, N. Defer, Mol. Cell. Endocrinol. 128 (1–2) (1997) 179.
[11] D. Willoughby, D.M. Cooper, Physiol. Rev. 87 (3) (2007) 965.
[12] J. Zhang, M. Sato, E. Duzie, S.W. Kubalak, S.M. Lanier, J.G. Webb, Am. J. Physiol. 273 (2 Pt 2) (1997) H971.
[13] R.S. Ostrom, J.E. Naugle, M. Hase, C. Gregorian, J.S. Swaney, P.A. Insel, L.L. Brunton, J.G. Meszaros, J. Biol. Chem. 278 (27) (2003) 24461.
[14] M.A. Beazely, V.J. Watts, Biochem. Pharmacol. 70 (1) (2005) 113.
[15] M.T. Walsh, B.T. Kinlessa, Br. J. Pharmacol. 131 (3) (2000) 601.
[16] L.P. Kelley-Hickie, B.T. Kinlessa, Br. J. Pharmacol. 142 (1) (2004) 203.
[17] S.J. Wilson, A.M. Roche, E. Kostetskaia, E.M. Smyth, J. Biol. Chem. 279 (51) (2004) 53036.
[18] K.J. Sales, S. Maudsley, H.N. Jabbour, Mol. Endocrinol. 18 (6) (2004) 1533.
[19] K.J. Sales, S.C. Boddy, A.R. Williams, R.A. Anderson, H.N. Jabbour, Endocrinology 148 (8) (2007) 3635.
[20] R.P. Millar, J. Davidson, C.A. Flanagan, L. Wakefield, Methods in Neurosciences, Receptor Molecular Biology, Academic Press, San Diego, 1995, p. 145.
[21] W. Huber, A. von Heydebreck, H. Sultmann, A. Poustka, M. Vingron, Bioinformatics 18 (Suppl 1) (2002) S96.
[22] G.K. Smyth, Stat. Appl. Genet. Mol. Biol. 3 (2004) Article 3.
[23] Y. Benjamiini, Y. Hochberg, J. R. Stat. Soc. Ser. B 57 (1995) 289.
[24] B. Zhang, S. Kirov, J. Snoddy, Nucleic Acids Res. 33 (2005) W741 Web Server issue.
[25] R.M. Breyer, C.K. Bagdassarian, S.A. Myers, M.D. Breyer, Annu. Rev. Pharmacol. Toxicol. 41 (2001) 661.
[26] T. Watanabe, A. Nakao, D. Emeraldin, Y. Hashimoto, K. Tsukamoto, Y. Horie, M. Kinoshita, K. Kurokawa, J. Biol. Chem. 269 (26) (1994) 17619.
[27] J. Hanoune, N. Defer, Annu. Rev. Pharmacol. Toxicol. 41 (2001) 145.
[28] J.G. Meszaros, A.M. Gonzalez, Y. Endo-Mochizuki, S. Villegas, F. Villarreal, L.L. Brunton, Am. J. Physiol. Cell Physiol. 278 (1) (2000) 154.
[29] M.A. Lumsden, R.W. Kelly, D.T. Baird, Br. J. Obstet. Gynaecol. 88 (12) (1981) 1315.
[30] U. Karck, F. Reister, W. Scharf, H.P. Zabradnic, M. Breckvold, Prostaglandins 51 (1) (1996) 49.
[31] H. Fujino, K.A. West, J.W. Regan, J. Biol. Chem. 277 (4) (2002) 2614.
[32] B. Ashby, Biochem. Pharmacol. 55 (3) (1998) 239.
[33] R.A. Casero Jr., A.E. Pegg, FASEB J. 7 (8) (1993) 653.
[34] M. Fogel-Petrovic, D.L. Kramer, B. Ganis, R.A. Casero Jr., C.W. Porter, Biochim. Biophys. Acta 1216 (2) (1993) 255.
[35] A.E. Pegg, Am. J. Physiol. Endocrinol. Metab. 294 (6) (2008) E995.
[36] J. Hanoune, L. Allhonen, M. Pietila, T.A. Keinanen, Eur. J. Biochem. 271 (5) (2004) 877.
[37] J.M. Tucker, J.T. Murphy, N. Kriel, P. Diegelman, K.W. Barbour, C. Davis, M. Medda, L. Allhonen, J. Janne, D.L. Kramer, C.W. Porter, F.G. Berger, Cancer Res. 65 (12) (2005) 5390.
[38] C. Chen, B.A. Young, C.S. Coleman, A.E. Pegg, D. Sheppard, J. Cell Biol. 167 (1) (2004) 161.
[39] N.E. Vlahakis, B.A. Young, A. Ataklint, A.E. Hawkridge, R.B. Issaka, N. Boudreau, D. Sheppard, J. Biol. Chem. 282 (20) (2007) 15187.